Lake Street Capital Forecasts Strong Price Appreciation for Semler Scientific (NASDAQ:SMLR) Stock

Semler Scientific (NASDAQ:SMLR) had its target price hoisted by stock analysts at Lake Street Capital from $40.00 to $71.00 in a report issued on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. Lake Street Capital’s price target would suggest a potential upside of 28.02% from the stock’s previous close.

Semler Scientific Price Performance

SMLR opened at $55.46 on Friday. The firm’s fifty day moving average price is $60.44 and its two-hundred day moving average price is $40.35. The company has a market capitalization of $514.11 million, a P/E ratio of 27.05 and a beta of 1.18. Semler Scientific has a fifty-two week low of $20.88 and a fifty-two week high of $81.56.

Semler Scientific (NASDAQ:SMLR) last issued its earnings results on Monday, November 4th. The company reported $0.72 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.37 by $0.35. The business had revenue of $13.51 million during the quarter. Semler Scientific had a return on equity of 20.31% and a net margin of 27.00%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of SMLR. Newbridge Financial Services Group Inc. acquired a new stake in shares of Semler Scientific in the second quarter valued at $34,000. Quest Partners LLC lifted its position in shares of Semler Scientific by 48.0% during the third quarter. Quest Partners LLC now owns 2,520 shares of the company’s stock worth $59,000 after purchasing an additional 817 shares in the last quarter. US Bancorp DE grew its stake in shares of Semler Scientific by 60.8% during the third quarter. US Bancorp DE now owns 3,064 shares of the company’s stock valued at $72,000 after purchasing an additional 1,158 shares during the last quarter. Sanctuary Advisors LLC acquired a new position in Semler Scientific during the 3rd quarter worth $104,000. Finally, Rhumbline Advisers boosted its holdings in Semler Scientific by 27.1% in the second quarter. Rhumbline Advisers now owns 6,197 shares of the company’s stock valued at $213,000 after acquiring an additional 1,320 shares during the last quarter. 49.37% of the stock is owned by institutional investors and hedge funds.

Semler Scientific Company Profile

Semler Scientific, Inc provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States. The company’s products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient’s vascular condition.